HC Wainwright Estimates enGene’s Q1 Earnings (NASDAQ:ENGN)

enGene Holdings Inc. (NASDAQ:ENGN) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for enGene in a research note issued on Monday, December 23rd. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of ($0.41) per share for the quarter. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for enGene’s current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for enGene’s Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.61) EPS, FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.37 EPS.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06.

Other analysts also recently issued research reports about the company. Morgan Stanley restated an “overweight” rating and issued a $40.00 target price on shares of enGene in a research report on Wednesday, September 11th. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a report on Monday, November 18th. Raymond James began coverage on shares of enGene in a report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 target price on the stock. Oppenheimer reiterated an “outperform” rating and issued a $30.00 target price on shares of enGene in a research report on Tuesday, September 24th. Finally, JMP Securities restated a “market outperform” rating and set a $18.00 price target on shares of enGene in a research report on Monday. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $29.78.

enGene Trading Up 6.0 %

Shares of ENGN stock opened at $6.32 on Wednesday. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. The firm has a market cap of $279.45 million, a P/E ratio of -10.90 and a beta of -0.78. The business has a 50-day moving average price of $8.10 and a two-hundred day moving average price of $7.78. enGene has a 12-month low of $4.42 and a 12-month high of $18.40.

Institutional Investors Weigh In On enGene

Several institutional investors and hedge funds have recently modified their holdings of ENGN. Wolverine Asset Management LLC purchased a new position in shares of enGene during the third quarter valued at about $37,000. Point72 Asset Management L.P. boosted its position in enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after acquiring an additional 619,100 shares in the last quarter. SR One Capital Management LP purchased a new position in shares of enGene during the 2nd quarter worth approximately $4,715,000. Franklin Resources Inc. grew its holdings in shares of enGene by 48.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after acquiring an additional 389,918 shares during the period. Finally, Logos Global Management LP raised its position in shares of enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after acquiring an additional 400,000 shares in the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at enGene

In other enGene news, major shareholder Growth Opportunities F. Forbion acquired 41,639 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were purchased at an average cost of $5.97 per share, for a total transaction of $248,584.83. Following the transaction, the insider now owns 2,059,459 shares in the company, valued at $12,294,970.23. This represents a 2.06 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ronald Harold Wilfred Cooper bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average price of $5.70 per share, with a total value of $57,000.00. Following the acquisition, the chief executive officer now owns 10,000 shares of the company’s stock, valued at $57,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 420,965 shares of company stock worth $2,651,103. 13.70% of the stock is currently owned by company insiders.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.